Canara HSBC Life Insurance Company Ltd (CANHLIFE) Q1 FY27 Results Analysis: Solvency Rises to 198%, Expense Ratio Climbs to 20.7%

CompoundingAI Research Updated July 20, 2026 2 min read
Neutral

Canara HSBC Life Insurance Company Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 2,161.06 Cr (+23.70% YoY) and PAT growth of +20.20% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 20, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 2,161.06 Cr (+23.70% YoY)
PAT (Q1)Rs. 28.14 Cr (+20.20% YoY)
EPS (Q1)Rs. 0.30 (+20.00% YoY)
Market capRs. 14,269.00 Cr
CMPRs. 150.20

Quarter Snapshot

Canara HSBC Life Insurance delivered strong YoY growth in premiums and PAT, with solvency improving to 198%. However, expense management ratio rose to 20.7% and persistency softened, while the product mix shift toward traditional products is a positive for margins. The company's growth lagged the industry, indicating potential market share loss.

Key Investment Insights

Key Positives

  • Gross premium grew 23.7% YoY to Rs.2,161 Cr.
  • PAT grew 20.2% YoY to Rs.28.14 Cr.
  • Solvency ratio improved to 198% from 190% QoQ.
  • Product mix shifted toward traditional products (65.4% vs 61.2% YoY), supporting VNB margins.
  • Linked NP Life segment surplus swung to Rs.2,734 Lakhs from Rs.990 Lakhs YoY.
  • Shareholders' GNPA declined to 4.5% from 5.4% YoY.
  • No investor complaints received during the quarter.

Risk Factors

  • Expense of management ratio rose to 20.7% from 19.6% YoY, outpacing premium growth.
  • 13-month persistency declined to 81.8% from 82.5% YoY.
  • Gross premium growth (23.7% YoY) lagged industry NBP growth of 39% YoY, indicating potential market share loss.
  • Current ratio dropped to 1.03x from 1.36x, indicating tighter liquidity.
  • Contingent liabilities increased to Rs.345.8 Cr from Rs.319.9 Cr YoY.
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now